SynthesisBlood advances2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes.
Synthesis in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Guideline
- When plasmacytoma defies expectations: An unusual maxillary presentation with mixed imaging features in a young patient.Radiology case reports · 2026Article
- Penile Plasmacytoma: A Rare CaseTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.Blood advances · 2026Article
- Staged Surgical Resection of Giant Multicentric Cranial Plasma Cell Neoplasms: A Case Report.Cureus · 2026Article
- Solitary Plasmacytoma of the Rib: A Report of a Rare Case.The American journal of case reports · 2025Article
- Solitary Bone Plasmacytoma of the Scapula: A Rare Localization With Remarkable Radiotherapy Outcome.Cureus · 2025Article
- Solitary but not simple─a call for precision risk stratification and individualized treatment in solitary plasmacytoma.Leukemia · 2025Article
- Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.Journal of medicine and life · 2025Review
- Imaging Evaluation of Bone Tumors in the Cervical Spine: A Comprehensive Review.International journal of general medicine · 2025Review
- Isolated solitary plasmacytoma of the frontal region mimicking meningioma: A case report.Surgical neurology international · 2025Article
- Clinical characteristics and prognostic factors of patients with solitary plasmacytoma: a multicenter retrospective study.Therapeutic advances in hematology · 2025Article
- Palatal Solitary Plasmacytoma: A Case Report on Post-radiotherapy Challenges.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIn this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs 79 months, P < .05, observed in patients with true solitary plasmacytomas, with no clonal cells in the BM. Risk factors identified for shorter DFS included the presence of clonal plasma cells in the marrow and a difference between involved and uninvolved free light chains of >5 mg/dL. The meta-analysis portion of our study highlighted a male predominance among patients, with a median age of 58 years, and confirmed radiation therapy as the predominant treatment modality. We also found that DFS rates at 3, 5, and 10 years were 66.9%, 55%, and 42.1%, respectively, and noted a significant difference in outcomes between patients with bone and extramedullary plasmacytomas, with the latter group exhibiting better survival rates. This dual-faceted approach provides a thorough overview of survival rates and critical risk factors for patients with plasmacytoma, underscoring the vital role of accurate disease staging at diagnosis and the impact of tumor location on patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.